Nisa Investment Advisors LLC Has $31,000 Stock Position in OptimizeRx Co. (NASDAQ:OPRX)

Nisa Investment Advisors LLC raised its holdings in OptimizeRx Co. (NASDAQ:OPRX) by 215.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,142 shares of the company’s stock after purchasing an additional 1,462 shares during the quarter. Nisa Investment Advisors LLC’s holdings in OptimizeRx were worth $31,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Kennedy Capital Management LLC bought a new position in OptimizeRx in the third quarter valued at about $4,323,000. Jacob Asset Management of New York LLC grew its holdings in shares of OptimizeRx by 30.1% during the 3rd quarter. Jacob Asset Management of New York LLC now owns 370,330 shares of the company’s stock valued at $2,881,000 after purchasing an additional 85,720 shares during the last quarter. Quadrature Capital Ltd bought a new position in OptimizeRx in the 3rd quarter valued at approximately $162,000. Quantbot Technologies LP acquired a new stake in OptimizeRx in the third quarter valued at approximately $49,000. Finally, AWM Investment Company Inc. grew its stake in shares of OptimizeRx by 75.8% during the third quarter. AWM Investment Company Inc. now owns 782,571 shares of the company’s stock worth $6,088,000 after buying an additional 337,303 shares during the last quarter. Institutional investors own 76.47% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on OPRX shares. JMP Securities reissued a “market outperform” rating and set a $15.00 price objective on shares of OptimizeRx in a report on Tuesday, April 16th. Royal Bank of Canada reissued an “outperform” rating and set a $17.00 price target on shares of OptimizeRx in a research note on Monday, April 1st. Barclays started coverage on OptimizeRx in a research note on Wednesday, January 3rd. They issued an “equal weight” rating and a $15.00 price objective for the company. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $13.00 target price on shares of OptimizeRx in a research report on Monday, April 1st. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, OptimizeRx presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.86.

OptimizeRx Stock Down 2.5 %

OptimizeRx stock opened at $9.09 on Tuesday. The company has a quick ratio of 3.04, a current ratio of 3.04 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $165.26 million, a PE ratio of -9.00 and a beta of 0.98. The firm’s fifty day moving average is $13.11 and its 200 day moving average is $12.04. OptimizeRx Co. has a 12-month low of $6.92 and a 12-month high of $16.65.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow.